Shots:
- X-Chem to receive an up front and is eligible to receive research, development and regulatory milestone along with royalties on sales of therapies resulting from the collaboration
- Genentech will lead further development and commercialization of any potential new therapies and retain exclusive rights to compounds derived from the collaboration. Additionally, Genentech get an exclusive license to an existing preclinical, small molecule program previously identified by X-Chem using its DEL platform
- X-Chem will leverage its DEL platform to identify novel leads against multiple oncology targets of interest to Genentech and may also conduct hit-to-lead optimization for the programs
Click here to read full press release/ article | Ref: Businesswire | Image: Business Wire
The post Genentech Signs an Exclusive License Agreement with X-Chem to Discover Oncology Targets first appeared on PharmaShots.
